Compare Eli Lilly And Co (LLY) vs Workiva Inc (WK) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Workiva (WK) trades at $57.19, showing minimal daily movement with a 0.02% gain. The stock maintains a bullish technical outlook with strong analyst support (88.9% buy ratings) and a $71 consensus price target. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.77 surpassing the $0.66 estimate. Revenue growth continues with 2026 projections showing $926 million and a return to profitability at 1.53% net margin.

The outlook remains positive given Workiva's dominant market position in compliance software and AI-powered platform growth. Key risks include high valuation multiples (P/E 238.25) and competitive pressures in the enterprise software space. The stock offers 24% upside to consensus targets but requires monitoring of execution against elevated expectations.